|1.||Donnez, Jacques: 7 articles (08/2015 - 02/2012)|
|2.||Bouchard, Philippe: 7 articles (02/2015 - 09/2007)|
|3.||Xu, Qin: 7 articles (09/2011 - 02/2005)|
|4.||Maruo, Takeshi: 7 articles (09/2011 - 02/2005)|
|5.||Ohara, Noriyuki: 7 articles (09/2011 - 02/2005)|
|6.||Bestel, Elke: 5 articles (04/2015 - 02/2012)|
|7.||Osterloh, Ian: 5 articles (02/2015 - 02/2012)|
|8.||Sitruk-Ware, Regine: 5 articles (09/2011 - 02/2005)|
|9.||Chen, Wei: 5 articles (11/2010 - 02/2005)|
|10.||Gotteland, Jean-Pierre: 4 articles (04/2015 - 01/2013)|
|1.||Leiomyoma (Uterine Fibroids)
08/01/2014 - "Recent reports concerning administration of SPRMs, specifically the efficacy of ulipristal acetate in reducing fibroid size and rapid control of menstrual blood loss, have renewed clinical interest in this class of compound. "
05/28/2012 - "A significantly greater median reduction from baseline in total fibroid volume was observed for recipients of ulipristal acetate 5 mg once daily than recipients of placebo following 13 weeks' treatment (coprimary endpoint). "
08/01/2014 - "The SPRM ulipristal acetate is an effective treatment for preoperative treatment of fibroids and a reliable emergency contraceptive. "
08/01/2015 - "Ulipristal acetate has recently shown particular promise for providing long-term relief from uterine fibroids. "
05/01/2008 - "CDB-2914 improved the concern scores of the uterine leiomyoma symptom quality-of-life subscale (P=.04). "
09/01/2003 - "CDB-2914 at doses of 1-100 mg did not change luteal phase length, but after 200 mg, all women had early endometrial bleeding. "
01/01/2015 - "Ulipristal was associated with faster control of excessive menstrual bleeding, fewer symptoms of hot flashes and lower health care resource consumption. "
03/01/2014 - "Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo."
02/02/2012 - "Treatment with ulipristal acetate for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids. "
02/01/2011 - "Administration of CDB-2914 for 3-6 months controls bleeding, reduces fibroid size, and improves QOL."
|3.||Uterine Hemorrhage (Uterine Bleeding)
05/28/2012 - "Uterine bleeding was rapidly controlled by ulipristal acetate. "
02/02/2012 - "At 13 weeks, uterine bleeding was controlled in 91% of the women receiving 5 mg of ulipristal acetate, 92% of those receiving 10 mg of ulipristal acetate, and 19% of those receiving placebo (P<0.001 for the comparison of each dose of ulipristal acetate with placebo). "
09/01/2013 - "Superior efficacy of ulipristal acetate versus placebo, to reduce excessive uterine bleeding and to reduce total fibroid volume prior to surgery was demonstrated. "
05/28/2012 - "In two randomized, double-blind, multinational phase III trials of 13 weeks' duration in women aged 18-50 years with uterine fibroids, a once-daily regimen of oral ulipristal acetate 5 mg/day controlled excessive uterine bleeding (primary endpoint) in ≥90% of patients. "
01/01/2015 - "In addition to controlling abnormal uterine bleeding, newer medical therapies, including the recently Health-Canada-approved ulipristal acetate, act directly to shrink the tumor. "
09/01/2014 - "On the other hand, recent studies have demonstrated the efficacy of ulipristal acetate in the medical management of myomas. "
08/01/2015 - "To study the in vivo mechanisms of action of ulipristal acetate (UPA) on uterine myomas. "
08/01/2015 - "In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment."
04/01/2015 - "Description of a spontaneous expulsion of a submucosal myoma in a patient treated with ulipristal acetate. "
04/01/2015 - "Expulsion of a uterine myoma in a patient treated with ulipristal acetate."
12/01/2014 - "According to a post hoc analysis of clinical trials in several hundred obese or overweight women, levonorgestrel and ulipristal have uncertain efficacy in these patients. "
12/01/2014 - "EC pills are less effective for women who are overweight or obese, therefore such women should be offered a copper IUD or ulipristal rather than levonorgestrel pills. "
|2.||Mifepristone (RU 486)
|4.||Levonorgestrel (Plan B)
|5.||Gonadotropin-Releasing Hormone (GnRH)
|7.||epigallocatechin gallate (epigallocatechin-3-gallate)
|8.||Progesterone Receptors (Progesterone Receptor)
|10.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Postcoital Contraception (Emergency Contraception)
|4.||Uterine Artery Embolization